Personalized Outreach and Multifaceted Interventions for Screening Enhancement (PROMISE) for Anal and Cervical Cancer Prevention and Treatment

In the US, anal cancer (AC) and cervical cancer (CC) disproportionately affect the most vulnerable—those who must navigate complex, cumulative intersectionality that further constrains access to disease prevention. In South Florida and Georgia, the catchment areas for the Sylvester Comprehensive Cancer Center (Sylvester), and Winship Cancer Institute (Winship), AC and CC incidence remains high among Blacks and Hispanics of a variety of ancestries, particularly those in groups at high risk of poor outcome. The proposed PeRsonalized Outreach and Multifaceted Interventions for Screening Enhancement (PROMISE) for Anal and Cervical Cancer Prevention and Treatment SPORE will address differences in cancer incidence and outcome across different population groups by leveraging, via horizontal and vertical engagement, the robust infrastructure and capacity of three, top-tier research institutions, with an established history of collaboration. Sylvester, Winship, and Morehouse School of Medicine, individually and collectively, have been at the forefront of high-impact, translational science in AC and CC through validating screening modalities that circumvent multilevel impediments to disease prevention and early detection, as well as examining critical heterogeneity in disease etiology, onset, and progression. PROMISE will expand upon this work via three innovative, high-impact Research Projects, as well as pilot studies that seek to understand and/or address observed variability in disease outcomes across the cancer control continuum through our Developmental Research Program (DRP). Our commitment to community-engaged, translational science will inform the proposed activities of our Career Enhancement Program (CEP). All Projects and Programs will leverage the shared expertise of three proposed Cores: The Community Outreach and Engagement Core (COE), Biospecimen and Pathology Core, and Biostatistics and Bioinformatics Core. PROMISE partners are committed to 1) translating lessons learned from our work in AC and CC into a framework that addresses differences in cancer outcomes; and, 2) deepening the longstanding connections between our academic and community partners to meaningfully modify the landscape of anal and cervical cancer prevention, early detection, diagnosis, and treatment. Project Number: 1U54CA302465-01 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: Isabella Rosa-Cunha (+3 co-PIs) | Institution: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, CORAL GABLES, FL | Award Amount: $2,336,229 | Activity Code: U54 | Study Section: Special Emphasis Panel[ZCA1 RPRB-N (M1)] View on NIH RePORTER: https://reporter.nih.gov/project-details/11199468